Novavax's updated XBB.1.5 vaccine shows promising cross-neutralizing antibodies against new COVID-19 variants

The study reveals that Novavax's updated XBB.1.5 vaccine effectively induces cross-neutralizing antibodies against multiple Omicron XBB sub-variants in both mice and non-human primates.

Related Keywords

,Vijay Kumar Malesusep ,Vijay Kumar Malesu ,Novavax Inc ,European Medicines Agency ,Drug Administration ,Novavax Discovery Group ,World Health Organization ,Vijay Kumar ,Coronavirus Disease ,Induces Broadly Neutralizing ,Cellular Immune Responses Against ,Image Credit ,Severe Acute Respiratory Syndrome Coronavirus ,Novavax Discovery ,Human Embryonic Kidney ,Angiotensin Converting Enzyme ,Institutional Animal Care ,House Committees ,Graphpad Prism ,Bagg Albino Like ,Antibodies ,Covid 19 ,Vaccine ,Ntigen ,Essay ,D4 ,Fell ,Coronavirus ,Ytokine ,Efficacy ,Revolution ,Wood ,Immunity ,Immunization ,Micron ,Protein ,Pseudovirus ,Espiratory ,Cars ,Ars Cov 2 ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Spike Protein ,Yndrome ,